Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R E Toomey

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Endocrinology|December 11, 1992
Androgens lower prostaglandin E2 levels in neonatal mouse bulbourethral gland in in vitro culturesJ S Little, K L Best, R L Goode, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1988
Preclinical pharmacology of a new serotonergic receptor antagonist, LY281067M L Cohen, R W Fuller, K D Kurz, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1993
LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1K S Hirsch, C D Jones, J E Audia, et al.
The Prostate|January 1, 1993
Endocrine and antiprostatic effects of raloxifene (LY156758) in the male ratB L Neubauer, K L Best, J A Clemens, et al.
The Journal of Clinical Endocrinology and Metabolism|June 1, 1996
LY191704 inhibits type I steroid 5 alpha-reductase in human scalpB L Neubauer, H M Gray, C W Hanke, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Endocrinology|December 11, 1992
Androgens lower prostaglandin E2 levels in neonatal mouse bulbourethral gland in in vitro culturesJ S Little, K L Best, R L Goode, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1988
Preclinical pharmacology of a new serotonergic receptor antagonist, LY281067M L Cohen, R W Fuller, K D Kurz, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1993
LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1K S Hirsch, C D Jones, J E Audia, et al.
The Prostate|January 1, 1993
Endocrine and antiprostatic effects of raloxifene (LY156758) in the male ratB L Neubauer, K L Best, J A Clemens, et al.
The Journal of Clinical Endocrinology and Metabolism|June 1, 1996
LY191704 inhibits type I steroid 5 alpha-reductase in human scalpB L Neubauer, H M Gray, C W Hanke, et al.
Pageof 2